Yukiko Nishimura, the president of ASrid, gave a presentation at World Orphan Drug Congress 2017

NATIONAL PATIENT ORGANIZATIONS

Making rare and intractable diseases an Asian health priority

• Japanese ‘Specified Disease Treatment Research Program’ and Orphan drug legislation to encourage orphan drug research 
• J-Rare and ODOD (Open Discussion for Orphan Drug Discovery programs) to foster
  rare disease identification, registries and diagnosis
• Connecting Asian rare disease stakeholders to accelerate the path to treatment

Yukiko Nishimura, President, ASrid